- Datum22.01.2026
- Uhrzeit17:00 - 17:30 Uhr
- Veranstalter
stock3
Cellectis Act.Nom.(Sp.ADRs)/1 EO -,05 Chart inkl. Chartanalyse
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
Echtzeit-News zu diesem und anderen Unternehmen findest Du hier!
Live-Ticker Cellectis Act.Nom.(Sp.ADRs)/1 EO -,05 Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate BSX | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-0,24 %
Intraday
0,61 %
1 Woche
-12,37 %
1 Monat
-15,08 %
Seit Jahresbeginn
168,63 %
1 Jahr
34,31 %
3 Jahre
-86,86 %
5 Jahre
-82,80 %
10 Jahre
Passender Service zu Cellectis Act.Nom.(Sp.ADRs)/1 EO -,05
Webinar zu Cellectis Act.Nom.(Sp.ADRs)/1 EO -,05
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)1,100-5,480
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Cellectis Act.Nom.(Sp.ADRs)/1 EO -,05
Keine Dividenden verfügbar
Termine von Cellectis Act.Nom.(Sp.ADRs)/1 EO -,05
Keine aktuellen Termine
Beschreibung
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
